Skip to main content

Advertisement

Consensus clinical management guidelines for Friedreich ataxia

Article metrics

Abstract

Friedreich ataxia (FRDA), a multisystem autosomal recessive condition, is the most common inherited ataxia in Caucasians, affecting approximately 1 in 29,000 individuals. The hallmark clinical features of FRDA include progressive afferent and cerebellar ataxia, dysarthria, impaired vibration sense and proprioception, absent tendon reflexes in lower limbs, pyramidal weakness, scoliosis, foot deformity and cardiomyopathy. Despite significant progress in the search for disease modifying agents, the chronic progressive nature of FRDA continues to have a profound impact on the health and well-being of people with FRDA. At present there is no proven treatment that can slow the progression or eventual outcome of this life-shortening condition. Thirty-nine expert clinicians located in Europe, Australia, Canada and USA critically appraised the published evidence related to FRDA clinical care and provided this evidence in a concise manner. Where no published data specific to FRDA existed, recommendations were based on data related to similar conditions and/or expert consensus. There were 146 recommendations developed to ensure best practice in the delivery of health services to people with FRDA. Sixty-two percent of recommendations are based on expert opinion or good practice indicating the paucity of high-level quality clinical studies in this area. Whilst the development of these guidelines provides a critical first step in the provision of appropriate clinical care for people with FRDA, it also highlights the urgency of undertaking high-quality clinical studies that will ensure the delivery of optimum clinical management and intervention for people with FRDA.

Introduction

Friedreich ataxia (FRDA), the most common of the hereditary ataxias, is an autosomal recessive, multisystem disorder affecting approximately 1 in 29,000 individuals and has a carrier frequency of 1 in 85 in individuals of Caucasian background [1],[2]. The hallmark neurological features of FRDA include progressive afferent and cerebellar ataxia, dysarthria, fixation instability, impaired vibration sense and proprioception, and pyramidal weakness. Most affected individuals have absent lower limb reflexes, but some have retained reflexes and may have spasticity. Scoliosis, diabetes, foot deformity and cardiomyopathy are common non-neurological features [3]-[5]. Pathology related to FRDA includes degeneration of the dorsal root ganglia and posterior columns of the spinal cord, spinocerebellar tracts, corticospinal tracts, dentate nuclei of the cerebellum and the heart [6],[7]. FRDA is due to mutations in FXN [8]. In about 96% of mutant alleles there is homozygosity for a pathological expansion of a GAA trinucleotide repeat in intron one of FXN whilst in the other 4% there is compound heterozygosity for an intron 1 GAA repeat expansion in one allele and a point mutation or deletion in the other [8]-[10]. The GAA expansion results in a reduction of frataxin, a mitochondrial membrane protein involved in iron sulfur protein production, storage and transport [11],[12]. Since the discovery of the molecular basis underlying this disorder in 1996, there has been an abundance of studies exploring the nature of the mutation, the role of frataxin, disease progression and disease modifying agents [11],[13]-[15]. Although no specific therapies have been identified that can alter the course of this devastating disease, a number of promising compounds have been identified [11],[16]. However the challenge for clinicians to provide effective, evidence-based clinical management for the multifaceted issues facing people with FRDA endures.

In 2003, “Revalidatie Geneeskundige Richtlijn Ataxie van Friedreich” was written by a special task force under the auspices of ‘Vereniging Spierziekten Nederland’. These were the first guidelines that provided an evidence base to the clinical management of people with FRDA. These guidelines were subsequently updated and adapted for international use in September 2007 (http://www.vsn.nl/hulpverleners/protocol_detail.php?protocol_id=17). In 2009, Ataxia UK launched “Management of ataxia: towards best clinical practice”, developed to provide recommendations for the management of people with inherited ataxia, including FRDA (http://www.ataxia.org.uk/pages/resources-and-publications.html). Whilst this further initiative was welcomed, it was apparent that issues specific to FRDA required disease specific guidelines. Furthermore, it was apparent that the multiple gaps in evidence surrounding service delivery may provide a platform for ongoing research.

Method

Assembling the Executive Committee and Specialist Working Groups

An executive committee (MBD, DL, MP, JBS and LAC) was convened to oversee the process of guideline development. Clinicians with expertise in FRDA were recruited to contribute to the guidelines through invitations from the executive. Thirty-nine individuals participated in the writing of these guidelines. This group advanced the topics and corresponding clinical questions which would be the foundation of the guidelines. Specialist working groups (SWGs) related to specific topics were established. There were two face-to-face meetings during the guideline development phase that were attended by some of the 39 authors, otherwise communication was facilitated by teleconference and email. Each member of the SWGs was asked to formally declare any potential conflict of interest however none were present that required removal of any individual from the writing groups.

Developing topics and clinical questions

An initial topic list was developed by MBD and LAC. This list was refined by discussion with the executive and the SWGs (see Table 1 for the final topic list). The specific topics within the guidelines comprised a description of the topic, associated natural history, investigations, an evaluation of the evidence and graded recommendations. Where possible, clinical review questions were developed around the PICO framework (patients/population, intervention, comparison and outcome) [17] which formed the basis of the examination of available evidence.

Table 1 List of topics included in the clinical management guidelines

Literature search and evaluation of the literature

A literature review was conducted for each topic. Clinical databases included in the search were PubMed, MEDLINE, CINAHL, Best Practice, Cochrane Database of Systematic Reviews, EMBASE and Scopus. Guideline SWGs evaluated the available evidence according to the templates developed by the Guidelines International Network (http://www.g-i-n.net/) for diagnostic and intervention studies.

Grading of evidence and recommendations

A range of international methods of grading of evidence and recommendations were reviewed. These included those recommended by the American Academy of Neurology (AAN) (USA), Scottish Intercollegiate Guidelines Network (SIGN), National Institute of Health and Clinical Excellence (NICE) (UK) and the National Health and Medical Research Council (NHMRC) Australia. Given no one method was identified as clearly superior, the evidence and subsequent recommendations were graded according to the criteria developed by the NHMRC [18] (see Table 2 for levels of evidence and Table 3 for grading of recommendations). In order to indicate the strength of the body of evidence underscoring the recommendation and to ascertain if application of the evidence may result in improved health outcomes, recommendations were allocated a grading (A-D) according to the level of evidence (I to IV) available. Recommendations allocated Grade A were underpinned by a body of evidence that can be trusted to guide practice. Grade B recommendations included those for which a body of evidence can be trusted to guide practice in most situations. Grade C recommendations comprised those for which the body of evidence provides some support but care should be taken in its application, whereas an allocation of Grade D indicated the body of evidence underlying the recommendation is weak and must be applied with caution [18]. Where no clear Level I, II III or IV evidence was available but where there was sufficient consensus within the specialist working group, good practice points (GPP) were provided. A GPP is the recommended best practice based on clinical experience and the expert opinion of the SWG. SWGs were encouraged to consult widely with colleagues and peers to ensure consistency of evidence. Every effort was made to achieve consensus within the group. However for the sections on Dysarthria and Dysphagia, the recommendations were sent to the executive group for a final independent decision. On one occasion (Genetic testing of asymptomatic minors) no consensus was reached and both viewpoints are presented. Draft iterations of the guidelines were circulated to all authors involved in producing the guidelines for comment and feedback. The final draft was sent to advocacy groups representing individuals with FRDA.

Table 2 Levels of evidence and grading of recommendations (National Health and Medical Research Council 1999 [19])
Table 3 National Health and Medical Research Council grading of evidence for recommendations [18]

Results

The guidelines comprise 9 sections and 25 subsections (see Table 1). There are 146 recommendations related to 1) the neurological components of FRDA; 2) the heart, cardiovascular and respiratory system; 3) scoliosis; 4) diabetes mellitus; 5) genetic issues; 6) FRDA due to FXN compound heterozygosity; 7) pregnancy issues; 8) quality of life issues. There were three recommendations graded as A, six graded as B, 28 graded as C, 17 graded as D and 92 GPP. The full guidelines are available on the internet (http://www.curefa.org/physicians.html). The following provides a summation of the recommendations from each topic (Table 4).

Table 4 The neurological components of Friedreich ataxia

Conclusion

The molecular basis of Friedreich ataxia was established in 1996 [8]. The time since this pivotal discovery has seen an explosion in the understanding of the underlying mutation and the pathogenesis of the condition, the phenotype and potential pharmacological interventions. Despite this surge of information, significant gaps remain in understanding the best clinical interventions for people with FRDA. In the absence of treatments that lessen the impact of the condition, it is crucial that appropriate clinical intervention is explored and documented. This paper has reported the methodology and outcome of developing clinical management guidelines for people with FRDA. In so doing it has highlighted the disparate nature of FRDA requiring considerable depth and breadth in terms of clinical management expertise.

The principle purpose of clinical management guidelines is to provide “systematically developed statements to assist the practitioner and the patient to make decisions about appropriate health care for specific clinical circumstances” [75]. In addition clinical management guidelines play a significant role in identifying the gaps in the evidence and providing direction for ongoing high-quality studies that will underpin future iterations of the guidelines. Sixty-two percent of recommendations are based on expert opinion or good practice. For example areas such as the management of diabetes mellitus in FRDA, the complexity of genetic issues associated with symptomatic and presymptomatic testing, sexual function and quality of life have little evidence to reliably inform recommendations. In addition, areas such as the management of heart issues, dysarthria, dysphagia and scoliosis have low quality evidence guiding intervention. Whilst the development of these guidelines provides a critical first step in the provision of appropriate clinical care for people with FRDA, it also highlights the urgency of undertaking high-quality clinical studies that will ensure the delivery of optimum intervention for people with FRDA. These guidelines will be reviewed every three years and it is hoped subsequent iterations will rely less on expert opinion and more on high quality clinical studies.

Abbreviations

AAN:

American Academy of Neurology

EKG:

Electrocardiogram

FRDA:

Friedreich ataxia

FXN :

Frataxin

GAA:

Guanine-Adenine-Adenine

GPP:

Good practice point

LVEF:

Left ventricular ejection fraction

NHMRC:

National Health and Medical Research Council

NICE:

National Institute of Health and Clinical Excellence

NYHA:

New York Heart Association

OSA:

Obstructive sleep apnea

RLS:

Restless leg syndrome

SIGN:

Intercollegiate Guidelines Network

SWG:

Specialist Working Groups

References

  1. 1.

    Cossee M, Schmitt M, Campuzano V, Reutenauer L, Moutou C, Mandel JL, Koenig M: Evolution of the Friedreich’s ataxia trinucleotide repeat expansion: founder effect and premutations. Proc Natl Acad Sci U S A. 1997, 94: 7452-7457. 10.1073/pnas.94.14.7452.

  2. 2.

    Delatycki MB, Williamson R, Forrest SM: Friedreich ataxia: an overview. J Med Genet. 2000, 37: 1-8. 10.1136/jmg.37.1.1.

  3. 3.

    Delatycki MB, Paris DB, Gardner RJ, Nicholson GA, Nassif N, Storey E, MacMillan JC, Collins V, Williamson R, Forrest SM: Clinical and genetic study of Friedreich ataxia in an Australian population. Am J Med Genet. 1999, 87: 168-174. 10.1002/(SICI)1096-8628(19991119)87:2<168::AID-AJMG8>3.0.CO;2-2.

  4. 4.

    Dürr A, Cossee M, Agid Y, Campuzano V, Mignard C, Penet C, Mandel JL, Brice A, Koenig M: Clinical and genetic abnormalities in patients with Friedreich’s ataxia. N Eng J Med. 1996, 335: 1169-1175. 10.1056/NEJM199610173351601.

  5. 5.

    Schulz JB, Boesch S, Bürk K, Dürr A, Giunti P, Mariotti C, Pousset F, Schöls L, Vandan P, Pandolfo M: Diagnosis and treatment of Friedreich ataxia: a European perspective. Nat Rev Neurol. 2009, 5: 222-234. 10.1038/nrneurol.2009.26.

  6. 6.

    Pandolfo M: Friedreich ataxia. Semin Pediatr Neurol. 2003, 10 (3): 163-172. 10.1016/S1071-9091(03)00025-1.

  7. 7.

    Pandolfo M: Friedreich Ataxia: the clinical Picture. J Neurol. 2009, 256: 3-8. 10.1007/s00415-009-1002-3.

  8. 8.

    Campuzano V, Montermini L, Molto MD, Pianese L, Cossee M, Cavalcanti F, Monros E, Rodius F, Duclos F, Monticelli A: Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996, 271: 1423-1427. 10.1126/science.271.5254.1423.

  9. 9.

    Cossée M, Dürr A, Schmitt M, Dahl N, Trouillas P, Allinson P, Kostrzewa M, Nivelon-Chevallier A, Gustavson KH, Kohlschutter A, Muller U, Mandel JL, Brice A, Koenig M, Cavalcanti F, Tammaro A, De Michele G, Filla A, Cocozza S, Labuda M, Montermini L, Poirier J, Pandolfo M: Friedreich’s ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol. 1999, 45: 200-206. 10.1002/1531-8249(199902)45:2<200::AID-ANA10>3.0.CO;2-U.

  10. 10.

    Evans-Galea MV, Corben LA, Hasell J, Galea CA, Fahey MC, du Sart D, Delatycki MB: A novel deletion-insertion mutation identified in exon 3 of FXN in two siblings with a severe Friedreich ataxia phenotype. Neurogenetics. 2011, 12: 307-313. 10.1007/s10048-011-0296-3.

  11. 11.

    Santos R, Lefevre S, Sliwa S, Seguin A, Camadro J, Lesuisse E: Friedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities. Antioxid Redox Signal. 2010, 13: 651-690. 10.1089/ars.2009.3015.

  12. 12.

    Pandolfo M, Pastore A: The pathogenesis of Friedreich ataxia and the structure and function of frataxin. J Neurol. 2009, 256: 9-17. 10.1007/s00415-009-1003-2.

  13. 13.

    Forrest SM, Knight M, Delatycki MB, Paris D, Williamson R, King J, Yeung L, Nassif N, Nicholson GA: The correlation of clinical phenotype in Friedreich ataxia with the site of point mutations in the FRDA gene. Neurogenetics. 1998, 1: 253-257. 10.1007/s100480050037.

  14. 14.

    Pandolfo M: The molecular basis of Friedreich ataxia. Adv Exper Med Biol. 2002, 516: 99-118. 10.1007/978-1-4615-0117-6_5.

  15. 15.

    Puccio H, Koenig M: Recent advances in the molecular pathogenesis of Friedreich ataxia. Hum Mol Genet. 2000, 9: 887-892. 10.1093/hmg/9.6.887.

  16. 16.

    Kearney M, Orrell R, Fahey MC, Pandolfo M: Antioxidants and other pharmacological treatments for Friedreich ataxia (Review). Cochrane Rev 2012, 4.,

  17. 17.

    Schardt C, Adams MB, Owens T, Keitz S, Fontelo P: Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak. 2007, 7: 16-10.1186/1472-6947-7-16.

  18. 18.

    Hillier S, Grimmer-Somers K, Merlin T, Middleton P, Salisbury J, Tooher R, Weston A: FORM: An Australian method for formulating and grading recommendations in evidence-based clinical guidelines. BMC Med Res Methodol. 2011, 11: 23-10.1186/1471-2288-11-23.

  19. 19.

    NHMRC (1999) A Guide to the Development, Implementation and Evaluation of Clinical Practice Guideline. https://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/cp30.pdf.,

  20. 20.

    Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, Nurmikko T: EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010, 17: 1113-1188. 10.1111/j.1468-1331.2010.02999.x.

  21. 21.

    Dharmshaktu P, Tayal V, Kalra BS: Efficacy of antidepressants as analgesics: a review. J Clin Pharmacol. 2012, 52: 6-17. 10.1177/0091270010394852.

  22. 22.

    Olver J, Esquenazi A, Fung VS, Singer BJ, Ward AB: Botulinum toxin assessment, intervention and aftercare for lower limb disorders of movement and muscle tone in adults: international consensus statement. Eur J Neurol. 2010, 17: 57-73. 10.1111/j.1468-1331.2010.03128.x.

  23. 23.

    Katalinic OM, Harvey LA, Herbert RD, Moseley AM, Lannin NA, Schurr K: Stretch for the treatment and prevention of contractures. Cochrane Database Syst Rev 2010, Issue 9. Art. No.: CD007455. doi:10.1002/14651858.CD007455.pub2.,

  24. 24.

    Delatycki MB, Holian A, Corben L, Rawicki HB, Blackburn C, Hoare B, Toy M, Churchyard A: Surgery for equinovarus deformity in Friedreich’s ataxia improves mobility and independence. Clinical Orthopaedics & Related Research. 2005, 430: 138-141. 10.1097/01.blo.0000150339.74041.0e.

  25. 25.

    Synofzik M, Godau J, Lindig T, Schöls L, Berg D: Restless legs and substantia nigra hypoechogenicity are common features in Friedreich’s ataxia. Cerebellum. 2011, 10: 9-13. 10.1007/s12311-010-0215-4.

  26. 26.

    Frauscher B, Hering S, Högl B, Gschliesser V, Ulmer H, Poewe W, Boesch SM: Restless legs syndrome in Friedreich ataxia: a polysomnographic study. Mov Disord. 2011, 26: 302-306. 10.1002/mds.22769.

  27. 27.

    Hening WA, Allen RP, Washburn M, Lesage SR, Earley CJ: The four diagnostic criteria for restless legs syndrome are unable to exclude confounding conditions (“mimics”). Sleep Med. 2009, 10: 976-981. 10.1016/j.sleep.2008.09.015.

  28. 28.

    García-Borreguero D, Silber KR, Winkelman JW, Earley CJ, Högl B, Manconi M, Montplaisir J, Inoue Y, Allen RP: The long-term treatment of restless legs syndrome/Willis–Ekbom disease: evidence based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med. 2013, 14: 675-684. 10.1016/j.sleep.2013.05.016.

  29. 29.

    Blattner K: Friedreich’s ataxia: a suggested physical therapy regimen. Clinical Management. 1988, 8: 14-15.

  30. 30.

    Carr JH, Shepherd RB: Neurological Rehabilitation Optimising Motor Performance. 1998, Butterworth-Heinman, Oxford

  31. 31.

    Milne SC, Campagna EJ, Corben LA, Delatycki MB, Teo K, Churchyard AJ, Haines TP: Retrospective study of the effects of inpatient rehabilitation on improving and maintaining functional independence in people with friedreich ataxia. ArchivPhys Med Rehab. 2012, 93: 1860-1863. 10.1016/j.apmr.2012.03.026.

  32. 32.

    Folker J, Murdoch B, Cahill L, Delatycki M, Corben L, Vogel A: Dysarthria in Friedreich’s Ataxia: a perceptual analysis. Folia Phoniatrica et Logopedica. 2010, 62: 97-103. 10.1159/000287207.

  33. 33.

    Yorkston KM, Beukelman DR: Ataxic dysarthria: treatment sequences based on intelligibility and prosodic considerations. J Speech Hear Disord. 1981, 46: 398-404. 10.1044/jshd.4604.398.

  34. 34.

    Rosenbek JC, Robbins JA, Roecker EB, Coyle JL, Wood JL: A penetration-aspiration scale. Dysphagia. 1996, 11: 93-98. 10.1007/BF00417897.

  35. 35.

    Scott A, Perry A, Bench J: A study of interrater reliability when using videofluoroscopy as an assessment of swallowing. Dysphagia. 1998, 13: 223-227. 10.1007/PL00009576.

  36. 36.

    Carnaby G, Hankey GJ, Pizzi J: Behavioural intervention for dysphagia in acute stroke: a randomised controlled trial. Lancet Neurol. 2006, 5: 31-37. 10.1016/S1474-4422(05)70252-0.

  37. 37.

    Welch MV, Logemann JA, Rademaker AW, Kahrilas PJ: Changes in pharyngeal dimensions effected by chin tuck. Arch Phys Med Rehabil. 1993, 74: 178-181.

  38. 38.

    Logemann JA, Gensler G, Robbins J, Lindblad AS, Brandt D, Hind JA, Kosek S, Dikeman K, Kazandjian M, Gramigna GD, Lundy D, McGarvey-Toler S, Miller Gardner PJ: A randomized study of three interventions for aspiration of thin liquids in patients with dementia or Parkinson’s disease. J Speech Lang Hear Res. 2008, 51: 173-183. 10.1044/1092-4388(2008/013).

  39. 39.

    Rasley A, Logemann JA, Kahrilas PJ, Rademaker AW, Pauloski BR, Dodds WJ: Prevention of barium aspiration during videofluoroscopic swallowing studies: value of change in posture. Am J Roentgenol. 1993, 160: 1005-1009. 10.2214/ajr.160.5.8470567.

  40. 40.

    Germain I, Dufresne T, Gray-Donald K: A novel dysphagia diet improves the nutrient intake of institutionalized elders. J Am Diet Assoc. 2006, 106: 1614-1623. 10.1016/j.jada.2006.07.008.

  41. 41.

    Clavé P, de Kraa M, Arreola V, Girvent M, Farré R, Palomera E, Serra-Prat M: The effect of bolus viscosity on swallowing function in neurogenic dysphagia. Aliment Pharmacol Ther. 2006, 24: 1385-1394. 10.1111/j.1365-2036.2006.03118.x.

  42. 42.

    Thurtell MJ, Leigh RJ: Treatment of nystagmus. Curr Treat Options Neurol. 2012, 14: 60-72. 10.1007/s11940-011-0154-5.

  43. 43.

    Coyne KS, Kaplan SA, Chapple CR, Sexton CC, Kopp ZS, Bush EN, Aiyer LP, EpiLUTS Team: Risk factors and comorbid conditions associated with lower urinary tract symptoms: EpiLUTS. BJU Int. 2009, 103 (Supplement 3): 24-32. 10.1111/j.1464-410X.2009.08438.x.

  44. 44.

    Fowler CJ, Panicker JN, Drake M, Harris C, Harrison SC, Kirby M, Lucas M, Macleod N, Mangnall J, North A, Porter B, Reid S, Russell N, Watkiss K, Wells M: A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2009, 80: 470-477.

  45. 45.

    Rance G, Corben L, Barker E, Carew P, Chisari D, Rogers M, Dowell R, Jamaluddin S, Bryson RMD: Auditory perception in individuals with Friedreich’s ataxia. Audiol Neurotol. 2010, 15: 229-240. 10.1159/000255341.

  46. 46.

    Tye-Murray N: Foundations of Aural Rehabilitation: Children, Adults, and Their Family Members. 2009, Delmar, New York, 3

  47. 47.

    Rance G, Corben LA, Du Bourg E, King A, Delatycki MB: Successful treatment of auditory perceptual disorder in individuals with Friedreich ataxia. Neuroscience. 2010, 171: 552-555. 10.1016/j.neuroscience.2010.09.013.

  48. 48.

    Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW: 2009 focused update incorporated into the ACC/AHA, Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009, 2009 (119): 391-479.

  49. 49.

    Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO, Smith SC, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Faxon DP, Halperin JL, Hiratzka LF, Hunt SA, Krumholz HM, Kushner FG: Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation. 2008, 2008 (117): 350-408.

  50. 50.

    Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS: ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011, 2011 (123): 269-367. 10.1161/CIR.0b013e318214876d.

  51. 51.

    Corben LA, Ho M, Copland J, Tai G, Delatycki MB: Increased prevalence of sleep disordered breathing in Friedreich ataxia. Neurology. 2013, 81: 40-45. 10.1212/WNL.0b013e318297ef18.

  52. 52.

    Giles TL, Lasserson TJ, Smith BH, White J, Wright J, Cates CJ: Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev 2006, Issue 3. Art. No.: CD001106. doi:10.1002/14651858.CD001106.pub3.,

  53. 53.

    Mouloudi H, Katsanoulas C, Frantzeskos G: Requirements for muscle relaxation in Friedreich’s ataxia. Anaesthesia. 1998, 53: 177-180. 10.1046/j.1365-2044.1998.00233.x.

  54. 54.

    Bell CF, Kelly JM, Jones RS: Anaesthesia for Friedreich’s ataxia. Case report and review of the literature. Anaesthesia. 1986, 41: 296-301. 10.1111/j.1365-2044.1986.tb12792.x.

  55. 55.

    Tsirikos AI, Smith G: Scoliosis in Friedreich’s ataxia. J Bone Joint Surg. 2012, 94: 684-689. 10.1302/0301-620X.94B5.28391.

  56. 56.

    Allard P, Dansereau J, Thiry PS, Geoffroy G, Raso JV, Duhaime M: Scoliosis in Friedreich’s ataxia. Can J Neurol Sci. 1982, 9: 105-111.

  57. 57.

    Cady RB, Bobechko WP: Incidence, natural history, and treatment of scoliosis in Friedreich’s ataxia. J Pediatr Orthop. 1984, 4: 673-676. 10.1097/01241398-198411000-00003.

  58. 58.

    Jovanovic L, Peterson CM: Screening for gestational diabetes. Optimum timing and criteria for retesting. Diabetes. 1985, 34: 21-23. 10.2337/diab.34.2.S21.

  59. 59.

    Armstrong BA, Howat PW: Pregnancy in a woman with Friedreich’s ataxia complicated by pulmonary embolism. Austr N Z J Obst Gynaecol. 2002, 42: 88-90.

  60. 60.

    Friedman LS, Paulsen EK, Schadt KA, Brigatti KW, Driscoll DA, Farmer JM, Lynch DR: Pregnancy with Friedreich ataxia: a retrospective review of medical risks and psychosocial implications. Am J Obstet Gynecol. 2010, 203: 224-10.1016/j.ajog.2010.03.046.

  61. 61.

    Paul RH, Miller DA: Cesarean birth: how to reduce the rate. Am J Obstet Gynecol. 1995, 172: 1903-1907. 10.1016/0002-9378(95)91430-7.

  62. 62.

    MacKenzie WE: Pregnancy in women with Friedreich’s ataxia. Brit Med J Clin Res Ed. 1986, 293: 308-10.1136/bmj.293.6542.308.

  63. 63.

    Kubal K, Pasricha SK, Bhargava M: Spinal anesthesia in a patient with Friedreich’s ataxia. Anesth Analges. 1991, 72: 257-258. 10.1213/00000539-199102000-00022.

  64. 64.

    Enns GM, Kinsman SL, Perlman SL, Spicer KM, Abdenur JE, Cohen BH, Amagata A, Barnes A, Kheifets V, Shrader WD, Thoolen M, Blankenberg F, Miller G: Initial experience in the treatment of inherited mitochondrial disease with EPI-743. Mol Genet Metab. 2012, 105: 91-102. 10.1016/j.ymgme.2011.10.009.

  65. 65.

    Lynch DR, Willi SM, Wilson RB, Cotticelli MG, Brigatti KW, Deutsch EC, Kucheruk O, Shrader W, Rioux P, Miller G, Hawi A, Sciascia T: A0001 in friedreich ataxia: biochemical characterization and effects in a clinical trial. Mov Disord. 2012, 27: 1026-1033. 10.1002/mds.25058.

  66. 66.

    Cooper JM, Korlipara LV, Hart PE, Bradley JL, Schapira AH: Coenzyme Q10 and vitamin E deficiency in Friedreich’s ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur J Neurol. 2008, 15: 1371-1379. 10.1111/j.1468-1331.2008.02318.x.

  67. 67.

    Richardson TE, Kelly HN, Yu AE, JW S: Therapeutic strategies in Friedreich’s ataxia. Brain Res. 2013, 1514: 91-97. 10.1016/j.brainres.2013.04.005.

  68. 68.

    Hausse AO, Aggoun Y, Bonnet D, Sidi D, Munnich A, Rotig A, Rustin P: Idebenone and reduced cardiac hypertrophy in Friedreich’s ataxia. Heart. 2002, 87: 346-349. 10.1136/heart.87.4.346.

  69. 69.

    Artuch R, Aracil A, Mas A, Colome C, Rissech M, Monros E, Pineda M: Friedreich’s ataxia: idebenone treatment in early stage patients. Neuropediatrics. 2002, 33: 190-193. 10.1055/s-2002-34494.

  70. 70.

    Di Prospero N, Baker A, Jeffries N, Fischbeck K: Neurological effects of high-dose idebenone in patients with Friedreich’s ataxia: a randomised, placebo-controlled trial. Lancet Neurol. 2007, 16: 878-886. 10.1016/S1474-4422(07)70220-X.

  71. 71.

    Pineda M, Arpa J, Montero R, Aracil A, Domínguez F, Galván M, Mas A, Martorell L, Sierra C, Brandi N, García-Arumí E, Rissech M, Velasco D, Costa JA, Artuch R: Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up. Eur J Paediatr Neurol. 2008, 12: 470-475. 10.1016/j.ejpn.2007.11.006.

  72. 72.

    Lynch DR, Perlman SL, Meier T: A phase 3, double-blind, placebo-controlled trial of Idebenone in Friedreich ataxia. Arch Neurol. 2010, 67: 941-947.

  73. 73.

    Valasco-Sánchez D, Aracil A, Montero R, Mas A, Jiménez L, O’Callaghan M, Tondo M, Capdevila A, Blanch J, Artuch R, Pineda M: Combined therapy with idebenone and deferiprone in patients with Friedreich’s ataxia. Cerebellum. 2011, 10: 1-8. 10.1007/s12311-010-0212-7.

  74. 74.

    Boesch S, Sturm B, Hering S, Scheiber-Mojdehkar B, Steinkellner H, Goldenberg H, Poewe W: Neurological effects of recombinant human erythropoietin in Friedreich’s ataxia: a clinical pilot trial. Mov Disord. 2008, 23: 1940-1944. 10.1002/mds.22294.

  75. 75.

    Field MJ, Lohr K: Clinical Practice Guidelines: Directions for a New Program. 1990, National Academy Press, Washington, US

Download references

Acknowledgements

Our grateful thanks are extended to the Friedreich ataxia Research Alliance (FARA, USA) for funding this project. In addition we are grateful to each member of the Clinical Guidelines Writing Group for sharing their wisdom regarding the clinical management for people with Friedreich ataxia.

On behalf of the Clinical Management Guidelines Writing Group (in alphabetical order):

Laura Balcer, Ron Bartek, Claire Bates, Emma Campagna, Miriam Cnop, Alexandra Dürr, Anton Emmanuel, Jennifer Farmer, John Flynn, Lisa S. Friedman, Paola Giunti, Marios Hadjivassiliou, Michael Ho, Grazia Isaya, Mary Kearney, Melissa Loucas, Caterina Mariotti, Sarah Milne, Thierry Morlet, Andrew McGarry, Jalesh Panicker, Michael Parkinson, R Mark Payne, Roger Peverill, Gary Rance, Lucy Rodriguez, Kimberly A. Schadt, Lauren Seyer, S.H. Subramony, Kelly L. Sullivan, Adam Vogel, Eppie Yiu, Grace Yoon, Theresa A. Zesiewicz.

Author information

Correspondence to Martin B Delatycki.

Additional information

Competing interests

This project was funded by FARA (USA). Dr. Lynch receives grant support from the NIH, FARA, MDA, Edison pharmaceutical, and Viropharma, Dr. Schulz receives grant support from the BMBF and the EU 7th framework program. Dr Pandolfo receives grant support from FARA (USA) and the EU 7th Framework Program (EFACTS), Dr Delatycki and Dr Corben receive grant support from NHMRC, FARA (USA) and FARA (Australasia).

Authors’ contributions

LAC: Organization, execution, planning for project, analysis, contribution to content, writing of first draft of manuscript, review of manuscript. DL: Planning of project, execution, contribution to content and review of manuscript. MP: Planning for project, execution, contribution to content, review of manuscript. JBS: Planning for project, execution, contribution to content and review of manuscript. MBD: Conceptualization of project, organization, planning, execution, analysis, contribution to content and review of manuscript. All authors read and approved the final manuscript.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Corben, L.A., Lynch, D., Pandolfo, M. et al. Consensus clinical management guidelines for Friedreich ataxia. Orphanet J Rare Dis 9, 184 (2014) doi:10.1186/s13023-014-0184-7

Download citation

Keywords

  • Friedreich ataxia
  • Clinical
  • Guidelines
  • Evidence
  • Recommendations